Biomarin Pharma Expects $283M Pre-Tax Charges for IPR&D in Q3 2026
BioMarin Pharmaceutical Inc. anticipates pre-tax charges of $283 million in the third quarter of 2026, related to bought in-process research and development expenses.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.